{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:51:46Z","timestamp":1791139906042,"version":"4.1.0"},"reference-count":85,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T00:00:00Z","timestamp":1363046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1001403","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T20:49:13Z","timestamp":1363121353000},"page":"e1001403","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":230,"title":["Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes"],"prefix":"10.1371","volume":"10","author":[{"given":"Glen I.","family":"Spielmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit I.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftihia","family":"Linardatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Z.","family":"Rosenlicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","article-title":"Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008","volume":"20","author":"GC Alexander","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref2","article-title":"Bristol-Myers Squibb Company Q1 2009 earnings call transcript","author":"E Sigal","year":"2009","journal-title":"Seeking Alpha"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archgenpsychiatry.2009.81","article-title":"National patterns in antidepressant medication treatment","volume":"66","author":"M Olfson","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/MLR.0b013e31825fb21d","article-title":"Use of antipsychotics among older residents in VA nursing homes","volume":"50","author":"WF Gellad","year":"2012","journal-title":"Med Care"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the department of Veterans Affairs health care system","volume":"60","author":"DL Leslie","year":"2009","journal-title":"Psychiatr Serv"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"JC Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"GI Papakostas","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0447.2007.01130.x","article-title":"Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder","volume":"117","author":"RC Shelton","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"ref9","first-page":"CD008121","article-title":"Second-generation antipsychotics for major depressive disorder and dysthymia","volume":"2010","author":"K Komossa","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"EH Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e1001189","DOI":"10.1371\/journal.pmed.1001189","article-title":"Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database","volume":"9","author":"EH Turner","year":"2012","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"D Eyding","year":"2010","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"JJ Kirkham","year":"2010","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/10673229.2011.614099","article-title":"Quality of life: the ultimate outcome measure of interventions in major depressive disorder","volume":"19","author":"WW Ishak","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00023210-200519040-00004","article-title":"Social functioning: should it become an endpoint in trials of antidepressants?","volume":"19","author":"P Bech","year":"2005","journal-title":"CNS Drugs"},{"key":"ref16","first-page":"295","article-title":"The assessment of outcomes in depression: measures of social functioning","volume":"11","author":"D Healy","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"ref17","first-page":"1","article-title":"Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature","volume":"8","author":"AC Tsai","year":"2011","journal-title":"PLoS Med"},{"key":"ref18","first-page":"819","article-title":"Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers?","volume":"25","author":"FK Goodwin","year":"2011","journal-title":"CNS Drugs"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients","volume":"23","author":"AL Montejo-Gonzalez","year":"1997","journal-title":"J Sex Marital Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4088\/JCP.08m04978blu","article-title":"Underrecognition of clinically significant side effects in depressed outpatients","volume":"71","author":"M Zimmerman","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"J Savovic","year":"2012","journal-title":"Ann Intern Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"7","author":"KF Schulz","year":"2010","journal-title":"PLoS Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"S Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"M Hamilton","year":"1960","journal-title":"J Neurol Neurosurg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"SA Corya","year":"2006","journal-title":"Depress Anxiety"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance","volume":"66","author":"RC Shelton","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"RC Shelton","year":"2001","journal-title":"Am J Psychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence","volume":"48","author":"E Frank","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-1781(86)90060-0","article-title":"The Inventory for Depressive Symptomatology (IDS): preliminary findings","volume":"18","author":"AJ Rush","year":"1986","journal-title":"Psychiatry Res"},{"key":"ref30","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"J Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36)","volume":"30","author":"J Ware","year":"1992","journal-title":"Med Care"},{"issue":"(Suppl 3)","key":"ref32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"D Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"ref33","unstructured":"Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. San Diego: Academic Press."},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"A Laupacis","year":"1988","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"JJ Deeks","year":"2002","journal-title":"Stat Med"},{"key":"ref36","unstructured":"Cates CJ (2012) Visual RX, version 3 [computer program]. <comment>Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nntonline.net\/visualrx\/\" xlink:type=\"simple\">http:\/\/www.nntonline.net\/visualrx\/<\/ext-link>. Accessed 2 September 2012.<\/comment>"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JPT Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref40","unstructured":"Biostat (2010) Comprehensive meta-analysis. Version 2.2.057, Englewood, NJ."},{"key":"ref41","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis","volume":"95","author":"S Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study)","volume":"81","author":"M Fava","year":"2012","journal-title":"Psychother Psychosom"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1756-0500-5-52","article-title":"Meta-analyses and forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptive data analysis","volume":"5","author":"JL Neyeloff","year":"2012","journal-title":"BMC Res Notes"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"RA Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref45","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale (New Jersey): Erlbaum."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"I Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/bmj.331.7509.155","article-title":"Efficacy of antidepressants in adults","volume":"331","author":"J Moncrieff","year":"2005","journal-title":"BMJ"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/bmj.39510.531597.80","article-title":"Efficacy of antidepressants","volume":"336","author":"EH Turner","year":"2008","journal-title":"BMJ"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jad.2010.08.032","article-title":"A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder","volume":"127","author":"M Bauer","year":"2010","journal-title":"J Affect Disord"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP task force on response and remission in major depressive disorder","volume":"31","author":"AJ Rush","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cct.2006.10.012","article-title":"Clinical trials and the response rate illusion","volume":"28","author":"I Kirsch","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"ref52","unstructured":"ClinicalTrials.gov (2011) Study comparing adjunctive risperidone versus placebo in major depressive disorder that is not responding to standard therapy. <comment>Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00095134\" xlink:type=\"simple\">http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00095134<\/ext-link>. Accessed 6 February 2013.<\/comment>"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/sj.npp.1301322","article-title":"Corrigendum: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation","volume":"32","author":"MH Rapaport","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JCP.0b013e318193c9b1","article-title":"Aripiprazole in refractory depression?","volume":"29","author":"B Carroll","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","article-title":"The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research","volume":"29","author":"PE McKnight","year":"2009","journal-title":"Clin Psychol Rev"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1017\/S1461145704004365","article-title":"Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression","volume":"7","author":"P Bech","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo","volume":"31","author":"BW Dunlop","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0269881108089602","article-title":"Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"23","author":"K Hewett","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/0269881109106953","article-title":"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","volume":"24","author":"K Hewett","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0b013e3181d420a7","article-title":"Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"30","author":"J Zajecka","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.genhosppsych.2003.07.004","article-title":"Quality of life assessments in major depressive disorder: a review of the literature","volume":"26","author":"GI Papakostas","year":"2004","journal-title":"Gen Hosp Psychiatry"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1503\/cmaj.071068","article-title":"Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials","volume":"178","author":"D Deshauer","year":"2008","journal-title":"CMAJ"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","article-title":"Simpson&apos;s paradox and calculation of number needed to treat from meta-analysis","volume":"2","author":"CJ Cates","year":"2002","journal-title":"BMC Med Res Methodol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10879-008-9094-0","article-title":"Sexual side effects of antidepressant medications: an informed consent-accountability gap","volume":"39","author":"AS Bahrick","year":"2009","journal-title":"J Contemp Psychother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1176\/ajp.2006.163.9.1504","article-title":"SSRI-associated sexual dysfunction","volume":"163","author":"R Balon","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-144-4-200602210-00007","article-title":"Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial","volume":"144","author":"S Bent","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref67","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research (2006) Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products\u2014content and format. <comment>Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm075057.pdf\" xlink:type=\"simple\">http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm075057.pdf<\/ext-link>. Accessed 4 September 2012.<\/comment>"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/archpsyc.1997.01830200078011","article-title":"Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial","volume":"54","author":"M Ba\u015fo\u011flu","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/JCP.v62n0202","article-title":"Prevention of recurrent postpartum depression: a randomized clinical trial","volume":"62","author":"KL Wisner","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ajp.2009.09060820","article-title":"Assuring that double-blind is blind","volume":"167","author":"RH Perlis","year":"2010","journal-title":"Am J Psychiatry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1192\/bjp.172.3.227","article-title":"Meta-analysis of trials comparing antidepressants with active placebos","volume":"172","author":"J Moncrieff","year":"1998","journal-title":"Br J Psychiatry"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/ije\/dym020","article-title":"Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding","volume":"36","author":"A Hrobjartsson","year":"2007","journal-title":"Int J Epidemiol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"GI Keitner","year":"2009","journal-title":"J Psychiatr Res"},{"key":"ref74","unstructured":"Zhang J, Mahjoob K, Yang P (2007) Statistical review and evaluation. NDA 21-436\/S_018. Abilify (aripiprazole). Aripiprazole as adjunctive treatment of major depressive disorder. Center for Drug Evaluation and Research. <comment>Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021436s018_StatR.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021436s018_StatR.pdf<\/ext-link>. Accessed 10 January 2012.<\/comment>"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"RM Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"RN Marcus","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"H Reeves","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"LL Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/JCP.0b013e318194087c","article-title":"Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al","volume":"29","author":"AC Tsai","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"K Dwan","year":"2008","journal-title":"PLoS ONE"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"M Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"RM Berman","year":"2009","journal-title":"CNS Spectr"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"N El-Khalili","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.20275","article-title":"Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study","volume":"24","author":"A McIntyre","year":"2007","journal-title":"Depress Anxiety"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"ME Thase","year":"2007","journal-title":"J Clin Psychiatry"}],"container-title":["PLoS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1001403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T05:17:26Z","timestamp":1589001446000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1001403"}},"subtitle":[],"editor":[{"given":"Phillipa J.","family":"Hay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,12]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1001403","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,12]]}}}